Also: All the news and watercooler chat from Fortune.
Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...
Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire ...
SAN FRANCISCO, Jan 12 (Reuters) - Pfizer (PFE.N), opens new tab is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ...
In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...
Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...
Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results